MicroRNAs in Pancreatic Cancer Drug Resistance: Mechanisms and Therapeutic Potential

Overview

Journal Front Cell Dev Biol

Date 2025 Jan 30

PMID 39882259

Authors

Fangying Dong

Jing Zhou

Yijie Wu

Zhaofeng Gao

Weiwei Li

Zhengwei Song

Affiliations

Soon will be listed here.

Abstract

Pancreatic cancer (PC) remains one of the most lethal malignancies, primarily due to its intrinsic resistance to conventional therapies. MicroRNAs (miRNAs), key regulators of gene expression, have been identified as crucial modulators of drug resistance mechanisms in this cancer type. This review synthesizes recent advancements in our understanding of how miRNAs influence treatment efficacy in PC. We have thoroughly summarized and discussed the complex role of miRNA in mediating drug resistance in PC treatment. By highlighting specific miRNAs that are implicated in drug resistance pathways, we provide insights into their functional mechanisms and interactions with key molecular targets. We also explore the potential of miRNA-based strategies as novel therapeutic approaches and diagnostic tools to overcome resistance and improve patient outcomes. Despite promising developments, challenges such as specificity, stability, and effective delivery of miRNA-based therapeutics remain. This review aims to offer a critical perspective on current research and propose future directions for leveraging miRNA-based interventions in the fight against PC.

References

Lu H, Lu S, Yang D, Zhang L, Ye J, Li M . MiR-20a-5p regulates gemcitabine chemosensitivity by targeting RRM2 in pancreatic cancer cells and serves as a predictor for gemcitabine-based chemotherapy. Biosci Rep. 2019; 39(5). PMC: 6504660. DOI: 10.1042/BSR20181374. View

Okusaka T, Furuse J . Recent advances in chemotherapy for pancreatic cancer: evidence from Japan and recommendations in guidelines. J Gastroenterol. 2020; 55(4):369-382. PMC: 7080663. DOI: 10.1007/s00535-020-01666-y. View

Ferro R, Adamska A, Lattanzio R, Mavrommati I, Edling C, Arifin S . GPR55 signalling promotes proliferation of pancreatic cancer cells and tumour growth in mice, and its inhibition increases effects of gemcitabine. Oncogene. 2018; 37(49):6368-6382. DOI: 10.1038/s41388-018-0390-1. View

Baradaran B, Shahbazi R, Khordadmehr M . Dysregulation of key microRNAs in pancreatic cancer development. Biomed Pharmacother. 2018; 109:1008-1015. DOI: 10.1016/j.biopha.2018.10.177. View

Huang J, Egger M, Grizzle W, McNally L . MicroRNA-100 regulates IGF1-receptor expression in metastatic pancreatic cancer cells. Biotech Histochem. 2013; 88(7):397-402. PMC: 4170730. DOI: 10.3109/10520295.2012.762460. View

Kim V, Nam J . Genomics of microRNA. Trends Genet. 2006; 22(3):165-73. DOI: 10.1016/j.tig.2006.01.003. View

Wang P, Zhang J, Zhang L, Zhu Z, Fan J, Chen L . MicroRNA 23b regulates autophagy associated with radioresistance of pancreatic cancer cells. Gastroenterology. 2013; 145(5):1133-1143.e12. DOI: 10.1053/j.gastro.2013.07.048. View

Shao Y, Zhang L, Cui L, Lou W, Wang D, Lu W . LIN28B suppresses microRNA let-7b expression to promote CD44+/LIN28B+ human pancreatic cancer stem cell proliferation and invasion. Am J Cancer Res. 2015; 5(9):2643-59. PMC: 4633895. View

Zhou L, Jia S, Ding G, Zhang M, Yu W, Wu Z . Down-regulation of miR-30a-5p is Associated with Poor Prognosis and Promotes Chemoresistance of Gemcitabine in Pancreatic Ductal Adenocarcinoma. J Cancer. 2019; 10(21):5031-5040. PMC: 6775620. DOI: 10.7150/jca.31191. View

10.

Liu L, Han S, Xiao X, An X, Gladkich J, Hinz U . Glucocorticoid-induced microRNA-378 signaling mediates the progression of pancreatic cancer by enhancing autophagy. Cell Death Dis. 2022; 13(12):1052. PMC: 9763328. DOI: 10.1038/s41419-022-05503-3. View

11.

Meng Q, Liang C, Hua J, Zhang B, Liu J, Zhang Y . A miR-146a-5p/TRAF6/NF-kB p65 axis regulates pancreatic cancer chemoresistance: functional validation and clinical significance. Theranostics. 2020; 10(9):3967-3979. PMC: 7086345. DOI: 10.7150/thno.40566. View

12.

Fathi M, Ghafouri-Fard S, Abak A, Taheri M . Emerging roles of miRNAs in the development of pancreatic cancer. Biomed Pharmacother. 2021; 141:111914. DOI: 10.1016/j.biopha.2021.111914. View

13.

Park W, Chawla A, OReilly E . Pancreatic Cancer: A Review. JAMA. 2021; 326(9):851-862. PMC: 9363152. DOI: 10.1001/jama.2021.13027. View

14.

Pang W, Su J, Wang Y, Feng H, Dai X, Yuan Y . Pancreatic cancer-secreted miR-155 implicates in the conversion from normal fibroblasts to cancer-associated fibroblasts. Cancer Sci. 2015; 106(10):1362-9. PMC: 4638007. DOI: 10.1111/cas.12747. View

15.

Abo-Al-Ela H, Faggio C . MicroRNA-mediated stress response in bivalve species. Ecotoxicol Environ Saf. 2020; 208:111442. DOI: 10.1016/j.ecoenv.2020.111442. View

16.

Chen X, Kang R, Kroemer G, Tang D . Targeting ferroptosis in pancreatic cancer: a double-edged sword. Trends Cancer. 2021; 7(10):891-901. DOI: 10.1016/j.trecan.2021.04.005. View

17.

Sun W, Li Y, Huang H, Shyy J, Chien S . microRNA: a master regulator of cellular processes for bioengineering systems. Annu Rev Biomed Eng. 2010; 12:1-27. DOI: 10.1146/annurev-bioeng-070909-105314. View

18.

Richards K, Zeleniak A, Fishel M, Wu J, Littlepage L, Hill R . Cancer-associated fibroblast exosomes regulate survival and proliferation of pancreatic cancer cells. Oncogene. 2016; 36(13):1770-1778. PMC: 5366272. DOI: 10.1038/onc.2016.353. View

19.

Sicard F, Gayral M, Lulka H, Buscail L, Cordelier P . Targeting miR-21 for the therapy of pancreatic cancer. Mol Ther. 2013; 21(5):986-94. PMC: 3666633. DOI: 10.1038/mt.2013.35. View

20.

Xie F, Li C, Zhang X, Peng W, Wen T . MiR-143-3p suppresses tumorigenesis in pancreatic ductal adenocarcinoma by targeting KRAS. Biomed Pharmacother. 2019; 119:109424. DOI: 10.1016/j.biopha.2019.109424. View